In the KRAS G12C-mutated CT26 mouse model, MRTX849 reduced myeloid-derived suppressor cells in the tumor, while increasing the infiltration of M1-type macrophages, dendritic cells, and CD4+ and CD8+ T cells, demonstrating a significant tumor-shrinking effect (144). Here, CD8A is linked to neoplasm.